ORMP Overview

Rights Agreement Adoption: Oramed Pharmaceuticals has adopted a Rights Agreement to protect stockholders in the event of a hostile takeover, allowing them to purchase shares at a set price if certain ownership thresholds are met.

Details of the Rights: Each Right allows stockholders to buy one share of Common Stock at $10.00, becoming exercisable if a person or group acquires 15% or more of the company's stock, with specific terms for redemption and exchange.

Dividend Distribution: A dividend of one Right will be distributed for each outstanding share of Common Stock, payable on November 27, 2025, to stockholders of record as of that date.

Forward-Looking Statements: The press release includes forward-looking statements regarding the Rights Plan and its potential effects, emphasizing that actual results may differ due to various uncertainties.

Strong Financial Performance: Oramed Pharmaceuticals reported a net income of $65 million for the nine months ending September 30, 2025, a significant turnaround from a net loss of $6.1 million in the same period last year.

Asset Growth: The company's total assets increased by 42% year-over-year, rising from $155.3 million to $220.5 million, reflecting robust balance sheet growth.

Investment Returns: The financial improvement was largely driven by cash returns from Scilex Holding Company and unrealized gains from investments in Alpha Tau Medical Ltd. and others.

Management Insights: CEO Nadav Kidron emphasized the effectiveness of their disciplined investment strategy, which has enhanced financial flexibility and supports ongoing development of their oral drug delivery platform.

Oral Insulin Program Update: Oramed Pharmaceuticals is advancing its oral insulin program independently, launching a new U.S. trial to validate its formulation based on promising results from identified high-responder subgroups.

Investment Portfolio Performance: The company has strategically invested in various biomedical firms, achieving significant returns, including a $99.5 million loan to Scilex and investments in Alpha Tau and BioXcel, which have shown substantial gains.

Shareholder Commitment: Oramed reaffirms its commitment to rewarding shareholders, including plans for a one-time dividend, despite the termination of a joint venture that would have facilitated this.

Growth Strategy and Financial Health: The company reports a growth in total cash and assets to approximately $210 million, highlighting its ability to create value through strategic capital deployment and a diversified investment approach.